• news.cision.com/
  • BioArctic/
  • Invitation to presentation of BioArctic’s Interim Report for the period January - March 2021 on April 21 at 9.30 a.m. CET

Invitation to presentation of BioArctic’s Interim Report for the period January - March 2021 on April 21 at 9.30 a.m. CET

Report this content

Stockholm, Sweden, April 15, 2021 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) 
will publish the company’s Interim Report for the period January – March 2021 on 
Wednesday, April 21, 2021, at 08:00 a.m. CET.

In conjunction to the report, BioArctic invites investors, analysts, and media to an audiocast with teleconference (in English) on April 21, at 09:30 CET, where Gunilla Osswald, CEO, and Jan Mattsson, CFO, will present BioArctic and comment on the Interim Report for the period January – March 2021, followed by a Q&A-session. 

To attend, please dial-in at one of the numbers below, from:

Sweden: +46 8 505 583 51 
Denmark: +45 781 501 08 
Germany: +49 692 222 203 77 
The Netherlands: +31 107 129 162 
Norway: +47 239 639 38 
Switzerland: +41 225 675 632 
UK: + 44 333 300 9032 
US: + 1 833 249 8405 

Webcast: https://tv.streamfabriken.com/bioarctic-q1-2021

 The webcast will also be available on demand on BioArctic’s corporate website https://www.bioarctic.se/en/section/investors/presentations/ after the presentation.

---

This information was submitted for publication at 08:00 a.m. CET on April 15, 2021. 

For more information, please contact:
Oskar Bosson, VP Communications and Investor Relations, BioArctic AB
E-mail: oskar.bosson@bioarctic.se  
Tel: + 46 704 10 71 80

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential. BioArctic’s Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.